MoonLake Immunotherapeutics (MLTX) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 14 Buy, 2 Hold, 2 Sell.
The consensus price target is $25.25 (low: $10.00, high: $35.00), representing an upside of 34.5% from the current price $18.78.
Analysts estimate Earnings Per Share (EPS) of $-1.79 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1,919.51 vs est $-1.79 (missed -107285.2%). 2025: actual $-3.53 vs est $-3.57 (beat +1%). Analyst accuracy: 50%.
MLTX Stock — 12-Month Price Forecast
$25.25
▲ +34.45% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for MoonLake Immunotherapeutics, the average price target is $25.25, with a high forecast of $35.00, and a low forecast of $10.00.
The average price target represents a +34.45% change from the last price of $18.78.
Highest Price Target
$35.00
Average Price Target
$25.25
Lowest Price Target
$10.00
MLTX Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to MoonLake Immunotherapeutics in the past 3 months
EPS Estimates — MLTX
50%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1,919.51
vs Est –$1.79
▼ 99.9% off
2025
Actual –$3.53
vs Est –$3.57
▲ 1.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — MLTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
